Centronuclear Myopathy

Centronuclear myopathy (CNM) is a group of rare, inherited neuromuscular disorders characterized by abnormal positioning of nuclei within muscle fibers. Clinical presentation varies by genetic subtype and may include congenital or childhood-onset muscle weakness, reduced muscle tone, delayed motor development, respiratory insufficiency, feeding difficulties, and ophthalmoplegia. Adult-onset and milder forms also occur, creating substantial variation in diagnosis, care needs, and long-term outcomes.

The CNM landscape is being reshaped by improved recognition of genotype–phenotype relationships, wider use of next-generation sequencing, and increased attention to respiratory, nutritional, orthopedic, and rehabilitative management. Diagnosis can remain difficult because symptoms overlap with other congenital myopathies and muscular dystrophies. Multidisciplinary care, genetic counseling, longitudinal functional assessment, and structured transition from pediatric to adult services are increasingly important for reducing avoidable complications and improving continuity of support.

Artificial intelligence can support CNM research and clinical practice by identifying phenotype patterns in electronic health records, prioritizing variants for review, improving interpretation of muscle imaging, and helping researchers connect dispersed rare-disease datasets. Its value depends on clinically representative training data, transparent validation, privacy safeguards, and expert oversight. AI should complement-not replace-neuromuscular specialists, genetic counselors, respiratory teams, and patients in diagnostic and treatment decisions.

North America generally benefits from established neuromuscular centers, genetic testing access, patient advocacy, and rare-disease research infrastructure, although geographic and insurance-related gaps remain. Europe has strong specialist networks and cross-border research potential, while differences in national reimbursement and referral pathways affect access. Asia-Pacific combines advanced capabilities in countries such as Japan, Australia, South Korea, and China with substantial variation in testing availability and specialist coverage. Latin America continues to face barriers related to delayed diagnosis, limited genomic access, and uneven multidisciplinary services. In the Middle East, specialist capacity is expanding but remains heterogeneous, particularly outside major urban centers. Africa faces the most pronounced constraints in genetic testing, specialist availability, registries, and sustained supportive care.

ASEAN countries face varied diagnostic infrastructure and opportunities to strengthen shared referral and sequencing networks. BRICS members represent diverse health systems with important potential for registry development, local expertise, and affordability-focused care models. The European Union supports collaboration through cross-border rare-disease initiatives, although implementation differs among member states. G7 countries contribute substantial research, specialist care, and policy capacity while continuing to address equitable access. GCC states are investing in advanced healthcare and genomics, with opportunities to improve regional coordination and family-centered counseling. NATO members span different health systems but can benefit from shared emergency preparedness, rehabilitation standards, and cross-border scientific collaboration.

Australia and Canada can build on specialist networks and publicly supported rare-disease programs while addressing distance-related access barriers. Brazil, Mexico, India, and Russia require stronger referral pathways, genetic testing availability, and multidisciplinary coverage across large and diverse populations. China, Japan, and South Korea have expanding genomic and neuromuscular capabilities, with continued opportunities to improve national registries and consistent access beyond major centers. France, Germany, Italy, Spain, and the United Kingdom have established clinical and research expertise, but reimbursement, regional service variation, and transition between care settings remain relevant priorities. The United States has extensive specialist and research capacity, alongside persistent challenges involving affordability, fragmented care, and unequal access.

Industry and health-system leaders should support referral algorithms for suspected congenital myopathies, broaden access to validated genetic testing, and connect diagnostic laboratories with expert interpretation. Care pathways should integrate respiratory surveillance, nutrition, physiotherapy, occupational therapy, orthopedic assessment, psychosocial support, and genetic counseling. Leaders should also invest in interoperable registries, patient-reported outcomes, natural-history studies, and ethically governed data partnerships. Any emerging therapy or digital tool should be evaluated with clinically meaningful functional, respiratory, and quality-of-life outcomes, while access planning should account for rural communities, lower-resource settings, and lifelong care requirements.

This executive summary uses a qualitative evidence-synthesis approach focused on verified clinical and health-system knowledge about centronuclear myopathy. The framework considers disease biology, presentation, diagnosis, supportive management, research infrastructure, regional conditions, and the potential role of artificial intelligence. Regional, group, and country narratives are comparative and contextual rather than quantitative. No market estimates, market sizing, market shares, forecasts, or company-specific claims are included; conclusions should be checked against current clinical guidelines, regulatory information, and local health-system evidence before implementation.

Progress in CNM depends on connecting earlier recognition with reliable genetic diagnosis, coordinated multidisciplinary management, patient-centered research, and equitable access to specialist expertise. Regional disparities will not be resolved by technology alone: sustainable registries, trained professionals, supportive policy, and meaningful patient participation are equally important. A coordinated approach can improve clinical decision-making, strengthen natural-history evidence, and create a more responsive care environment for individuals and families living with centronuclear myopathy.